Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

prnewswire.com - 2026-07-03 12:34:00

NEW YORK--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's leadership in advancing high-quality scientific evidence and innovating for patients. These new data – spanning aortic, mitral and tricuspid therapies – provide further understanding of the complexity of structural heart disease and the need for innovative treatment options.

businesswire.com - 2026-06-26 10:15:00

EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense today announced the launch of the SWH1530VP, a next-generation dual-enclave 100/40 Gigabit Ethernet switch engineered to provide secure, deterministic, and high-performance networking for modern Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance, Reconnaissance (C5ISR), Electronic Warfare (EW), and edge computing applications. Aligned with SOSA™, CMOSS, and OpenVPX™ standards, the 3U VPX module combines advanced La.

businesswire.com - 2026-06-22 07:01:00

On June 17, 2026, we present a DCF analysis for Edwards Lifesciences Corp (EW). The company has shown a price performance of +1.2% over the past week, +8.8% ove

gurufocus.com - 2026-06-17 07:27:00

On Monday, the Centers for Medicare & Medicaid Services (CMS) proposed removing the coverage with evidence development (CED) requirement for Transcatheter Aortic Valve Replacement (TAVR) in patients with symptomatic severe aortic stenosis.

benzinga.com - 2026-06-16 13:52:47

Edwards gains from strong TMTT growth, RESILIA adoption and expanding TAVR use, but macro pressures and currency swings remain key risks.

zacks.com - 2026-06-12 09:36:14

Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - East West Minerals Ltd. (TSXV: EW) ("East West" or the "Company") announces that further to a price reservation filed on June 10, 2026, the Company has arranged a non-brokered private placement financing (the "Financing") of up to 7,800,000 units (each a "Unit"), at a price of $0.11 per Unit, to raise up to $858,000.

newsfilecorp.com - 2026-06-12 08:00:00

On May 22, 2026, Edwards Lifesciences Corp (EW) shares rose 3.1% to a current price of $85.78. The stock has fluctuated between $72.30 and $87.89 over the past

gurufocus.com - 2026-05-22 17:20:00

On May 13, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown varied price performance recently. The stock has ex

gurufocus.com - 2026-05-13 08:15:00

Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-12 20:30:44

On May 11, 2026, Edwards Lifesciences Corp (EW) shares fell 3.5%, bringing the current price to $77.17. The stock has experienced a 52-week range of $72.30 to $

gurufocus.com - 2026-05-11 19:45:00

Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) and Novo Nordisk (NVO), advances in diagnostics from Natera (NTRA), and continued strength in med tech leaders like Intuitive Surgical (ISRG) and Edwards Lifesciences (EW) as key areas of expansion.

youtube.com - 2026-05-10 14:30:53

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced the appointment of Theodora (“Doretta”) Mistras as the company's corporate vice president and chief financial officer (CFO), effective at the end of May. Mistras will succeed Scott Ullem, who announced in October his planned transition from the CFO role. Mistras joins Edwards from Viatris, where she has served as CFO since March 2024, leading the company's global finance organization and overseeing financial planni.

businesswire.com - 2026-05-04 16:45:00

CHICAGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting. As evidence increasingly supports treating patients earlier in the valve disease pathway, the need for durable valve solutions continues to grow. The COMMENCE trial provides prospectiv.

businesswire.com - 2026-05-02 11:50:00

During the quarter, we initiated new positions in Edwards Lifesciences, Eli Lilly and Roblox. In addition to Linde, Shopify and Amazon, we also added to Woodward and Spotify during the quarter. We ended our investment campaigns in Netflix, Snowflake and RELX during the quarter.

seekingalpha.com - 2026-04-29 11:13:00

On April 29, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown mixed price performance recently. Over the past w

gurufocus.com - 2026-04-29 07:30:00

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026. Bernard Zovighian, chief executive officer, will participate in a fireside chat at 3:40 p.m. Pacific Time. A live webcast of the discussion will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com, with an archived version accessible later the same day. About Edwards Lifesciences.

businesswire.com - 2026-04-28 07:05:00

LENSAR (NASDAQ: LNSR - Get Free Report) and Edwards Lifesciences (NYSE: EW - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation. Volatility and Risk LENSAR has a beta of 0.99,

defenseworld.net - 2026-04-27 01:44:44

Modine Manufacturing led the way during the quarter, benefiting from secular demand in data center cooling and a well received spinoff of Modine Manufacturing's auto cooling business. Coming out of 2025, Adeia reported record revenue and profitability, supported by a surge in IP licensing activity. AtriCure remains well positioned given its first-mover advantage and deep integration within surgical workflows despite near-term competitive concerns from Edwards Lifesciences.

seekingalpha.com - 2026-04-26 22:10:00

Edwards Lifesciences beats on Q1 earnings, matches revenue estimates, lifts 2026 outlook as TAVR and TMTT growth accelerates; shares rise on stronger guidance and margin expansion.

zacks.com - 2026-04-24 15:21:28

Edwards Lifesciences Corp (NYSE:EW) shares are up on Friday as the company reported strong first-quarter results, highlighting growth in its transcatheter mitral and tricuspid therapies.

benzinga.com - 2026-04-24 12:50:05

Sales Growth: 12.7% year-over-year increase in Q1 2026.Total Sales: $1.65 billion in Q1 2026.TAVR Sales: $1.2 billion, 11% increase over the prior year.TMTT Sa

gurufocus.com - 2026-04-24 02:15:00

Edwards Lifesciences Corporation (EW) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-04-23 21:41:31

While the top- and bottom-line numbers for Edwards Lifesciences (EW) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

zacks.com - 2026-04-23 19:02:41

Edwards Lifesciences beat Wall Street first-quarter estimates on Thursday, driven by robust demand ​for its artificial valves used in complex ‌cardiac procedures, sending its shares up over 4% in extended trading.

reuters.com - 2026-04-23 17:51:46

Edwards Lifesciences stock advanced late Thursday on better-than-expected first-quarter sales and earnings.

investors.com - 2026-04-23 16:30:14

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2026. Highlights and Outlook Q1 sales grew 16.7% to $1.65 billion1, constant currency2 sales grew 12.7% Q1 TAVR sales grew 14.4% to $1.20 billion1; constant currency2 sales grew 11.0% Q1 TMTT sales of $173 million1,3, driven by repair and replacement therapies Q1 EPS of $0.661; adjusted2 EPS of $0.781 Raising FY 2026 constant currency2 sales growth guidance to 9% to.

businesswire.com - 2026-04-23 16:15:00

On April 23, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company currently trading at $81.53. The stock has shown some volatility

gurufocus.com - 2026-04-23 07:03:00

EW heads into Q1 earnings with TAVR strength, rising estimates and momentum in mitral and tricuspid therapies shaping expectations.

zacks.com - 2026-04-20 15:46:13

Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Edwards Lifesciences Corporation (NYSE: EW) by 27.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 109,749 shares of the medical research company's stock after buying an additional

defenseworld.net - 2026-04-20 05:17:01

Birch Hill Investment Advisors LLC reduced its position in shares of Edwards Lifesciences Corporation (NYSE: EW) by 1.8% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 743,680 shares of the medical research company's stock after selling 13,385

defenseworld.net - 2026-04-19 03:44:47

We are actively monitoring Meta Platforms' social and data privacy risks and believe the company has made progress on strengthening its policies and enforcement. We believe the market is underestimating the durability of Edwards' transcatheter aortic valve replacement franchise and the opportunity for its transcatheter mitral and tricuspid therapies. We exited our position in Workday to bring the portfolio's software exposure closer to market weight.

seekingalpha.com - 2026-04-17 10:11:00

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2026 after the market closes on Thursday April 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards Lifescie.

businesswire.com - 2026-04-16 07:05:00